S. Hannam , R. Nixon
Transdermal Rotigotine (Neupro) is a dopamine agonist indicated for the treatment of idiopathic Parkinson ’ s disease, either as monotherapy, or in combination with levodopa, and was recently approved by the TGA as symptomatic treatment of moderate to severe restless legs syndrome (RLS) in adults. RLS, often under diagnosed, is a neurological sensorimotor disorder, affecting patients at rest – mainly in the evening and night, with irresistible, involuntary and continuous limb movements and unpleasant paraesthesias, having a signiﬁ cant impact on daily functioning and quality of life. Application site reactions are common in transdermal drug delivery, and are most often the result of direct irritation from the drug substance or occlusive and/or adhesive qual- ities of the transdermal delivery system (TDS). Allergic contact dermatitis is far less common. Transdermal Rotigotine is a lipid-soluble dopamine agonist in a silicone base matrix patch that contains povidone, ascorbyl palmitate, dl-alpha tocopherol and sodium metabisulﬁ te. Application site skin reactions are cited as the most common adverse events (AEs) in clinical studies of Rotigotine, with up to 50% of patients reporting local cutaneous effects, manifest as erythema, pruritus, or pustules. The majority of these, however, are rated as mild to moderate and dose-related, (and considered to be of the irritant der- matitis subtype). Herein we report a case of severe allergic contact dermatitis in a 64 year old man with severe restless legs syndrome. This highlights the importance of clinicianawareness of the potential cutaneous side effects of transdermal Rotigotine when prescribing to patients.
A non-interventional-prospective-12-month study to characterise REAL-life effectiveness and treatmentpatterns of secukinumab, and current standard-of-care of chronic plaque psoriasis in Asia-Pacific & MiddleEast